Xencor, Inc. (XNCR) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
Is Xencor, Inc. stock overvalued or undervalued in 2026?
As of October 28, 2026, Xencor, Inc. (XNCR) trades at $29.99 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Xencor, Inc.
Market cap $2B · 52 weeks $10 – $30 (0 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS $-0.35 · Closing price, Oct 28 · accounts published Aug 5.
- Valuation: P/Sales 11.9× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Market cap / Cash 4.1×, fails.
- Cash Runway 49 meses, passes.
- Total Debt 0.4×, passes.
- R&D / Market cap 10.8 %, passes, near the threshold.
- Annual cash burn $1.82, info.
Against its peers (reference peers) — Xencor, Inc.: P/E —; EV/EBITDA —; ROIC -33.4 %; $2.2B. Nurix Therapeutics, Inc. (P/E 11.0×; EV/EBITDA 7.2×; ROIC 25.9 %; $2.8B), Genmab A/S (P/E 45.1×; EV/EBITDA 22.4×; ROIC 9.9 %; $35.2B), Aurinia Pharmaceuticals Inc. (P/E 7.6×; EV/EBITDA 10.6×; ROIC 21.3 %; $2.3B).
Profitability
| Return on Equity | -28.66% |
| Return on Invested Capital | -33.40% |
| Return on Assets | -22.53% |
| Gross Margin | 43.31% |
| Operating Margin | -205.84% |
| Net Margin | -155.59% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 6.39 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.73 |
Price Performance
| 1 month | +19.96% |
| 3 months | +48.39% |
| Year-to-date | +95.89% |
| 1 year | +104.43% |
| 3 years | +74.06% |
| 5 years | -24.19% |
| 10 years | +40.86% |
Related companies: GMAB · CLDX · NRIX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN
Explore sector: Healthcare · Biotechnology
More sections of XNCR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks